Acticor Biotech SAS Past Earnings Performance
Past criteria checks 0/6
Acticor Biotech SAS's earnings have been declining at an average annual rate of -26.3%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-26.3%
Earnings growth rate
-2.0%
EPS growth rate
Biotechs Industry Growth | 30.8% |
Revenue growth rate | n/a |
Return on equity | -5,067.7% |
Net Margin | n/a |
Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Acticor Biotech SAS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 0 | -19 | 5 | 11 |
31 Mar 23 | 0 | -17 | 5 | 11 |
31 Dec 22 | 0 | -16 | 5 | 10 |
30 Sep 22 | 0 | -15 | 5 | 9 |
30 Jun 22 | 0 | -14 | 5 | 8 |
31 Mar 22 | 0 | -13 | 5 | 8 |
31 Dec 21 | 0 | -13 | 4 | 8 |
30 Sep 21 | 0 | -11 | 3 | 8 |
30 Jun 21 | 0 | -10 | 2 | 8 |
31 Mar 21 | 0 | -9 | 2 | 7 |
31 Dec 20 | 0 | -8 | 2 | 6 |
31 Dec 19 | 0 | -5 | 2 | 4 |
31 Dec 18 | 0 | -6 | 2 | 4 |
Quality Earnings: ALACT is currently unprofitable.
Growing Profit Margin: ALACT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALACT is unprofitable, and losses have increased over the past 5 years at a rate of 26.3% per year.
Accelerating Growth: Unable to compare ALACT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALACT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: ALACT has a negative Return on Equity (-5067.66%), as it is currently unprofitable.